Delmar pharmaceuticals, inc. (DMPI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Expenses
Research and development

-4,031

-4,194

-3,959

-3,662

-10,286

-9,243

-8,048

-7,132

-2,087

-2,780

-3,801

-5,003

5,697

3,821

3,489

3,360

2,576

4,008

3,831

2,555

2,194

933

-244

-133

-1,160

90

989

1,779

1,928

1,550

0

0

0

-

-

-

-

-

-

General and administrative

-4,488

-4,630

-4,809

-4,736

-4,156

-3,936

-3,799

-4,041

-2,991

-3,448

-3,889

-3,317

4,704

3,376

3,695

2,853

2,191

3,322

3,087

2,168

3,435

1,968

675

379

-690

1,197

2,206

3,166

1,907

1,154

785

0

0

-

0

-

-

-

-

Revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

0

0

0

0

-

Marketing

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Professional Fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

11

6

10

17

20

0

0

0

Consulting Fee

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

Other Selling General and Administrative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

7

12

14

11

0

0

0

-

Operating expenses

-8,520

-8,825

-8,768

-8,398

-14,443

-13,180

-11,848

-11,174

-5,078

-6,229

-7,690

-8,320

10,402

7,197

7,185

6,214

4,767

7,330

6,919

4,724

5,629

2,901

430

245

-1,850

1,287

2,492

4,242

3,131

2,001

2,009

0

0

0

-

0

-

-

-

Other (income) loss
Change in fair value of derivative liability

-

-

-

-433

-117

-114

-116

-60

-246

-326

36

-245

2,536

2,336

2,655

2,341

-182

-687

-474

627

-1,091

1,288

24

-8,633

-11,466

-15,609

-15,237

-7,142

0

-

0

0

-

-

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability due to change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on exchange of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares to Valent for future royalty reduction

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

598

598

598

0

-

0

0

-

-

-

-

-

-

-

Derivative issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,713

2,713

2,713

0

-

0

0

-

-

-

-

-

-

-

Foreign exchange (gain) loss

35

26

23

17

97

97

95

57

-36

-36

-21

7

0

0

0

-

39

43

-8

-23

-14

4

46

41

69

60

17

42

9

18

0

0

0

-

-

-

-

-

-

Change in fair value of derivative liability due to change in warrant terms

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-295

-562

-555

-169

-23

310

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-36

-39

-51

-60

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

3

1

-0

-0

-4

-0

3

7

7

7

0

0

0

-

-

-

-

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

1

0

-0

-0

-0

-0

0

1

0

-

0

0

-

-

-

-

-

-

-

Other (income) loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other loss (income)

-309

-321

-334

-350

-9

-15

-35

-36

-277

-363

14

-239

0

0

0

-

-

-248

-566

376

-1,557

999

14

-8,481

-11,394

-18,859

-18,240

-10,123

-5,558

304

0

0

0

-

-

-

-

-

-

Weighted average number of shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

30,974

24,316

3,944

-

14,321

12,561

3,944

5,950

-

-

-

-

Total Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Total Expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Operating Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-18

-24

-25

-29

-33

0

0

0

Net loss for the period

8,210

8,503

8,434

8,048

14,433

13,164

11,812

11,138

4,801

5,866

7,705

8,081

0

0

0

-

-

-

-

-

-

-

-

-

-

-20,147

-7,427

-14,650

-8,974

-1,980

-1,988

-1,564

-433

-25

-29

-33

0

0

0

Computation of basic loss per share
Net and comprehensive loss for the year

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Currency translation adjustment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-0

-0

-0

0

0

0

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

0

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Comprehensive Loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Basic and fully diluted loss per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.10

0.24

-

-

-

-

-

-

-

-

-

-0.22

-0.30

0.00

-

-0.08

-0.03

0.00

0.00

0.00

0.00

-

0.00

Net loss for the period

8,210

8,503

8,434

8,048

14,433

13,164

11,812

11,138

4,801

5,866

7,705

8,081

0

0

0

-

-

-

-

-

-

-

-

-

-

-20,147

-21,016

-14,650

-8,974

-1,980

-1,988

-1,564

-433

-25

-29

-33

0

0

0

Series B Preferred stock dividend

-149

-128

-114

-80

-243

-219

-181

-176

-710

-547

-441

-790

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recapitalization loss on reverse acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

-

-

-

-

-

Net loss and recapitalization loss on reverse acquisition, total

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

0

-

-

-

-

-

-

Translation to US dollar presentation currency

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

15

-9

-17

-21

0

0

0

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-992

-4,219

-7,485

-4,347

-7,187

-1,901

-2,148

3,129

2,313

-8,290

-7,832

-15,079

-9,411

-2,421

0

0

0

-

-

-

-

-

-

Net and comprehensive loss for the period

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-992

-4,219

-7,485

-4,347

-7,187

-1,901

-2,148

3,129

2,313

-8,290

-7,832

-15,079

-9,411

-2,421

0

0

0

-

-

-

-

-

-

Series B Preferred stock dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss for the period attributable to common stockholders

8,360

8,631

8,548

8,128

14,677

13,384

11,994

11,314

931

1,832

3,566

8,872

5,975

9,193

13,322

9,103

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and fully diluted loss per share

0.17

0.15

0.21

0.86

0.67

0.75

0.88

3.79

1.31

0.14

0.18

0.20

0.18

0.13

0.23

-

-

-

0.15

0.35

0.05

0.02

0.04

-0.11

0.10

0.03

-0.22

-

-

-

-0.03

-

-

-

-

-

-

-

-

Diluted loss (income) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.11

0.10

0.03

-0.02

-

-

-

-0.03

-

-

-

-

-

-

-

-

Net Income (Loss) per share, basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.00

-

Basic and fully diluted number of shares

11,417

11,407

7,538

3,059

2,518

2,424

2,296

-31,790

2,283

22,559

15,292

13,887

11,574

11,424

11,301

11,101

11,077

10,994

10,620

-75,158

38,976

37,798

36,451

33,264

31,659

31,523

31,430

-

-

-

12,969

-

-

-

-

5,950

5,950

2,000

5,950

Diluted weighted average number of shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

51,506

31,659

31,523

41,671

-

-

-

12,969

-

-

-

-

-

-

-

-